Cargando…
A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy
Anti-CD20 treatment represents a therapeutic benefit for patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing patients. Among them, the combination of anti-CD20 and IL-2 that induces T cell response has been hampered by the expansion of FoxP3(+) Tr...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458652/ https://www.ncbi.nlm.nih.gov/pubmed/32923126 http://dx.doi.org/10.1080/2162402X.2020.1770565 |